Revenue Update on Galectin Therapeutics Inc(NASDAQ:GALT)

Galectin Therapeutics Inc(NASDAQ:GALT) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.12. The reported EPS was above estimates by 29.41%. Analysts had estimated an EPS of $-0.17.

Galectin Therapeutics Inc (GALT) made into the market gainers list on Fridays trading session with the shares advancing 3.29% or 0.07 points. Due to strong positive momentum, the stock ended at $2.2, which is also near the day’s high of $2.35. The stock began the session at $2.14 and the volume stood at 9,17,393 shares. The 52-week high of the shares is $3.05 and the 52 week low is $0.49. The company has a current market capitalization of $71 M and it has 3,22,10,849 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Nov 18, 2016, James C Czirr (director) sold 44,312 shares at $1.63 per share price.Also, On Jan 7, 2016, Arthur Greenberg (director) purchased 1,666 shares at $1.72 per share price.On Dec 2, 2015, Gilbert F Amelio (director) sold 100 shares at $2.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Galectin Therapeutics Inc. is a biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The company’s drug candidates are based on its method of targeting galectin proteins which are mediators of biologic and pathologic functions. It uses naturally occurring readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two compounds in development GRMD02 and GMCT01 both of which have shown promise in preclinical studies in treatment of fibrosis and in cancer therapy. The Company is focusing on the development of GRMD02 intended to be used in the treatment of liver fibrosis and fatty liver disease and in cancer therapy in combination with immunesystem modifying agent(s).

Add Comment